BSI Capital Group
Alejandra Paradones
CEO & FounderCalifornia Institute for Regenerative Medicine (CIRM)
Neil Littman
Business Development OfficerCDRD Ventures
CDRD Ventures Inc. (CVI) is the commercialization vehicle of the Centre for Drug Research and Development (CDRD), Canada's national drug development and commercialization center that was founded in 2007 and is based in Vancouver, Canada. CVI seeks to advance promising drug development projects from CDRD using internal funds and through partnerships with international pharmaceutical companies, venture capital firms, biotech companies, and other funding agencies. CVI also seeks to in-license technologies from industry or non-CDRD affiliated research institutions. The firm considers both small molecule and biologic innovative technologies in virtually any therapeutic area.
Ms Natalie Dakers
President & CEOMr Michael Lincoln
Chief Financial and Business OfficerChiesi Ventures
Art Pappas
PartnerCitareTx Investment Partners
CitareTx founded in 2008 is a venture development and investment firm based in Houston Texas. The firm provides investment and incubation services to start-up and early-stage medical device companies. The firm provides seed capital (equity) ranging from $5K to $2M with follow-on capital of up to $5M. The firm also considers investment opportunities with smaller than typically accepted venture capital market size thresholds. The firm is geographically agnostic but prefers companies to be based in Texas. The firm is actively seeking new opportunities.
Jeffery Sheldon
General Partner & Managing DirectorClayton Biotechnologies
Clayton Biotechnologies commercializes technologies that are developed and owned by the Clayton Foundation for Research and its supporting entities through research programs at leading research hospitals and institutions in the US and Switzerland.
We have several projects in various stages of development from discovery to advanced pre-clinical that are available for licensing, collaboration, and the creation of new start-up ventures.
Clayton Biotechnologies has a significant portfolio of technologies to offer for licensing and collaboration.
Some of our featured technologies:
- Urocortins and analogues for Diabetes
- Fc engineering of aglycosylated antibodies
- Granzyme B - a potent payload for antibody drug conjugates (ADC)
- Alk4-Fc, a Cripto antagonist for Cancer
- TEAD gene and peptide therapies for ocular neovascular disease
- Stem cell therapy program for Parkinson's Disease
- Vaccines and Diagnostics for Ehrlichioses
- Biomarker for personalized breast cancer therapy
- YESS - engineering of proteases
- OCT Image Guided Smart Laser Knife Diagnosis and Therapy in Small Spaces
To date, 9 products based on Clayton Foundation discoveries have been have been successfully commercialized through the creation of start-up companies and out-licensing
Alexandra Richardson
Head of Business DevelopmentColorado Institute for Drug Device and Diagnostic Development
The Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)3 not-for-profit entity committed to economic development through the creation and funding of Colorado Life Science companies. Our goal is to efficiently transform emerging life science innovations into commercial successes. First, we use a rigorous review process and advisory panel to select promising post-proof-of-concept technologies from Colorado’s outstanding research institutions and start-up companies. Second, we fund and actively manage product development while taking an equity position in existing companies and in new companies that we found with the inventors. Third, we facilitate additional seed and/or grant funding to further develop our portfolio companies technologies. By augmenting the value of these innovations, we position our portfolio companies to attract series A financing from venture capitalists and/or partnering opportunities with established pharmaceutical and biotechnology companies. We have funded 9 early stage companies since June 2010 and these companies have raised more than $30 million in additional private capital and grant funding.
Richard Duke
Founder & CSOCorrelation Ventures
Correlation Ventures is a venture capital firm that founded in 2010 and is based in San Diego, California with an additional office in Palo Alto, California. The firm currently has approximately $165 million in total assets under management. The firm typically makes investments ranging from $0.25 million to $5 million over the life of the company, and the first investment will be not larger than $2.5 million. The firm’s preferred capital structure is convertible preferred equity or convertible loan. Correlation Ventures will consider invest in any industry segment at any stage, but there must be at least one other venture capital firm making their first investment in the company in this round. The firm only invests in US-based companies.
Correlation is extremely opportunistic when it comes to investments in the life sciences space; with that being said the firm's specified sectors and sub sectors of interest may or may not be an area in which Correlation Ventures is currently looking to allocate capital to. The firm has made a number of investments in companies in the life sciences space, and has mainly invested in companies in the biotech therapeutics and diagnostics space. The firm's current portfolio includes biotech therapeutics and diagnostics firms developing products targeting endocrine, metabolic, and nutritional diseases, musculoskeletal system and connective tissue, neoplasms, cancer, and oncology, genitourinary system, and infectious and parasitic diseases.
David Coats
Managing DirectorDeep Knowledge Ventures
We are a Hong Kong-based venture fund management company focusing on mid- to long-term advanced technology investments at early stage. Through our partnership with the top analytical companies utilizing machine learning and large panel of experts, we can construct complex decision trees showing risk and return at every stage of company evolution. We routinely invest in both private and public companies specializing in biotechnology, drug discovery, personalized medicine, Big Data analysis, industrial expert systems and artificial intelligence.
Diamond BioFund
Diamond BioFund is an evergreen fund that was established in 2013 and is based in Taipei City, Taiwan. The fund is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in Taiwan-based businesses and co-invest in businesses overseas. The fund is currently seeking new opportunities in Taiwan, Greater China, Southeast Asia, US, Canada, and EU.
Diamond BioFund takes a generalist approach when considering life science opportunities, including therapeutics (small molecule and biologics), medical devices, diagnostics, healthcare services, and nutraceuticals. The fund is seeking cutting edge, innovative, and platform technology. In therapeutics, the fund considers all stages from preclinical through pre-IPO. In medical devices, the fund prefers later stage projects with proof of concept. The fund is open to all disease indications.